Dermatoonkologische Studien
Dermatoonkologische Studienambulanz
In unserer onkologischen Studienambulanz werden zahlreiche multizentrische klinische Studien zur adjuvanten und palliativen Melanomtherapie durchgeführt. Hinzu kommen klinische Studien zu anderen Hauttumorentitäten wie Basalzellkarzinome, aktinische Keratosen und kutane Lymphome. Wir nehmen teil an klinischen Studien der Arbeitsgemeinschaft Dermatologische Onkologie (ADO), der EORTC Melanomgruppe sowie durch verschiedene industrielle Partner. Einen Überblick über unsere aktuellen onkologischen Studien finden Sie hier.
Studien beim Malignen Melanom
Hier können Sie die Übersicht der aktuell rekrutierenden Studien herunterladen.
CA209-578, TRIM
A NATIONAL, PROSPECTIVE, NON-INTERVENTIONAL STUDY (NIS) OF NIVOLUMAB (BMS-936558) MONOTHERAPY OR IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED (UNRESECTABLE OR METASTATIC) MELANOMA
BERINGMelanoma
Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERINGMELANOMA
KRT-232-103
A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment
MK3475-630
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
R2810-ONC-1788
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
IFX-1-P2.8
OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1- RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
CERPASS
A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE 2 STUDY OF CEMIPLIMAB AS A SINGLE AGENT AND IN COMBINATION WITH RP1 IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
In Planung
